March 23, 2025 - 10:21
Today, the Obesity Action Coalition (OAC) and The Obesity Society (TOS) have taken a significant step by sending a letter to the U.S. Food and Drug Administration (FDA). This letter, supported by over 20 prominent organizations and providers from various sectors of healthcare, emphasizes the urgent need for the FDA to implement and enforce federal regulations concerning compounding practices.
The call to action comes in the wake of recent shortages of GLP-1 medications, which are crucial for the treatment of obesity and related conditions. These shortages have raised serious concerns about patient access to essential therapies. The coalition argues that without stricter oversight and regulation of compounded medications, patients may face continued disruptions in their treatment options.
Healthcare leaders are advocating for a timely response from the FDA to ensure that patients receive the medications they need without interruption, highlighting the importance of regulatory frameworks in safeguarding public health.
